EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive variant prostate cancer
Maryam Latarani, Perla Pucci, Mark Eccleston, Massimiliano Manzo, Priyadarsini Gangadharannambiar, Irene Fischetti, Ilaria Alborelli, Vera Mongiardini, Namra Mahmood, Mario Paolo Colombo, Benedetto Grimaldi, Sushilaben H. Rigas, Shusuke Akamatsu, Cheryl A. Hawkes, Yuzhuo Z. Wang, , Francesco Crea
This study shows that EZH2 inhibition enhances platinum chemotherapy effectiveness in aggressive variant prostate cancer by reducing H3K27me3 and modulating DNA repair and apoptosis pathways.
Epigenomics · Jan 29, 2025Peer-reviewedPharmacology & Toxicology